Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introducción: La enfermedad de Alzheimer (EA) representa la causa más común de demencia a nivel mundial, caracterizada por un deterioro progresivo de la memoria y otras funciones cognitivas. Si bien la acumulación de placas de beta-amiloide ha sido el principal blanco terapéutico durante décadas, los tratamientos actuales han mostrado beneficios clínicos limitados [7]. La reciente aprobación de anticuerpos monoclonales anti-amiloide ha reavivado el interés en este enfoque, aunque su eficacia y seguridad siguen siendo objeto de debate [1,3,6,8]. Paralelamente, han emergido estrategias terapéuticas dirigidas a mecanismos alternativos como la proteína tau, la neuroinflamación, el eje intestino-cerebro y la estimulación neuronal [2,5,15]. Objetivo: Realizar una revisión sistemática de la literatura científica reciente sobre terapias emergentes para la EA, con énfasis en anticuerpos monoclonales dirigidos contra el beta-amiloide y alternativas terapéuticas no amiloides. Métodos: Se realizó una búsqueda sistemática en PubMed, Scopus y Web of Science de artículos publicados entre enero de 2019 y mayo de 2025. Se incluyeron ensayos clínicos fase II-III, estudios preclínicos relevantes y revisiones sistemáticas que evaluaran eficacia, seguridad o mecanismos de acción de nuevas terapias en EA [2,5]. La selección y extracción de datos se realizó de manera independiente por dos revisores, siguiendo criterios PRISMA [11]. Resultados: Se identificaron 34 estudios relevantes. Los anticuerpos monoclonales como aducanumab, lecanemab y donanemab demostraron reducciones significativas en la carga amiloide cerebral, con efectos clínicos modestos y eventos adversos asociados, como edema vasogénico cerebral [1,4,6]. Las estrategias no amiloides, incluyendo anti-tau, inmunomoduladores, probióticos, estimulación transcraneal y terapia génica, muestran resultados preliminares prometedores, aunque aún requieren validación en estudios de fase avanzada [2,5,14,15]. Conclusión: Las terapias emergentes para la EA están ampliando el espectro de intervención más allá del paradigma amiloide. La combinación de enfoques dirigidos a múltiples mecanismos patogénicos podría representar el futuro del tratamiento personalizado en EA [14,15,17].

What this study adds

Evidence grade: Low

Anti-amyloid antibodies such as aducanumab, lecanemab and donanemab reduced amyloid burden in the brain but had only modest clinical effects and were linked to adverse events such as vasogenic brain edema. Non-amyloid approaches including anti-tau, immunomodulators, probiotics, transcranial stimulation and gene therapy show preliminary promising results but still need validation.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Knupflemacher, D. S., García, X. A. S., Salgado, C. N. A., Loyola, P. R., Arce, J. S., & Bautista, Á. G. P. (2025). Terapias emergentes para la enfermedad de Alzheimer: revisión sistemática de anticuerpos anti-amiloide y mecanismos alternativos. Revista Científica de Salud y Desarrollo Humano. https://doi.org/10.61368/r.s.d.h.v6i2.661

Vancouver

Knupflemacher DS, García XAS, Salgado CNA, Loyola PR, Arce JS, Bautista ÁGP. Terapias emergentes para la enfermedad de Alzheimer: revisión sistemática de anticuerpos anti-amiloide y mecanismos alternativos. Revista Científica de Salud y Desarrollo Humano. 2025. doi:10.61368/r.s.d.h.v6i2.661.

BibTeX

@article{knupflemacher2025-3c483de3,
  author  = {Knupflemacher, Daniel Sánchez and García, Xavier Antonio Sánchez and Salgado, Celina Nicole Angulo and Loyola, Paula Robert and Arce, Joel Santiago and Bautista, Ángel Gabriel Pérez},
  title   = {{Terapias emergentes para la enfermedad de Alzheimer: revisión sistemática de anticuerpos anti-amiloide y mecanismos alternativos}},
  journal = {Revista Científica de Salud y Desarrollo Humano},
  year    = {2025},
  doi     = {10.61368/r.s.d.h.v6i2.661},
  url     = {https://doi.org/10.61368/r.s.d.h.v6i2.661}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Anti-amyloid antibodies such as aducanumab, lecanemab and donanemab reduced amyloid burden in the brain but had only modest clinical effects and were linked to adverse events such as vasogenic brain edema. Non-amyloid approaches including anti-tau, immunomodulators, probiotics, transcranial stimulation and gene therapy show preliminary promising results but still need validation.

Study details

How this study scored 29/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 28 of the 96 points it could be judged on, which is 29 of 100. Total 29 of 100.28 of the 96 points we could judge = 29 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 28 of the 96 points we could judge it on, which is 29 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Revista Científica de Salud y Desarrollo Humano)
Journal's citation record 0 / 4 Revista Científica de Salud y Desarrollo Humano: journal h-index 21 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Ángel Gabriel Pérez Bautista holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Hospital Angeles Pedregal: institution h-index 53 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 28 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 28 of the 96 points we could judge it on is 29 out of 100.
Total 29 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →